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Abstract
Background—While persistent T-cell activation has been cross-sectionally associated with poor
CD4+ T-cell restoration in HIV-infected individuals maintaining antiretroviral treatment (ART)–
mediated viral suppression, it remains unclear whether CD8+ T-cell activation is of predictive
effect on CD4+ T-cell recovery.
Objective—We assessed whether the extent of persistent CD8+ T-cell activation (% CD38+/
HLA-DR+) in the fi rst few years of ART-mediated viral suppression predicted subsequent CD4+
T-cell recovery in 95 subjects with up to 15 years of observation on suppressive ART.
Results—Lower CD8+ T-cell activation and higher naïve CD4+ T-cell frequencies (CD45RA+/
CD62L+) measured at year 3 to 5 after starting ART independently predicted greater subsequent
CD4+ T-cell increases. The mean CD4 count increase from year 0 to year 5 and the increase to the
average of year 10 to 15 in the low CD8 activation group (≤18.5%; mean = 13%) were 342 and
458 cells/mm,3 and the increases were 248 and 349 cells/mm3 for the high CD8 activation group
(>18.5%; mean = 29%) (P = .002 and P = .016, respectively, comparing groups). At years 10 to
15, the mean CD4 counts in the groups were 579 and 484 cells/mm3, respectively (P = .026).
Conclusion—These fi ndings support the need to identify approaches to reduce immune
activation in treated HIV disease.
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Antiretroviral treatment (ART) substantially reduces the morbidity and mortality of human
immunodeficiency virus type-1 (HIV-1)–infected patients. However, HIV-infected patients
have widely variant CD4+ T-cell increases after ART, even if virally suppressed. Persistent
CD8+ T-cell activation during suppressive ART has been cross-sectionally associated with
poor CD4+ T-cell recovery, but no study has demonstrated that persistent T-cell activation
predicts subsequent CD4 recovery in long-term studies.
For example, Hunt et al reported that persistent CD8+ T-cell activation was associated with
fewer CD4+ T-cell gains from month 3 onwards in virally suppressed subjects during ART.1
Median follow-up was 21 months and the analysis was retrospective; the relationship
between T-cell activation and subsequent CD4+ T-cell recovery was not assessed. High
CD8+ T-cell activation was also associated with diminished concurrent CD4+ T-cell
recovery during ART in another study conducted by the ACTG.2 Other studies have
suggested that higher pre-ART CD8+ T-cell activation predicts poor CD4+ T-cell recovery
at week 483 or through a median of 3 years of suppressive ART.4 However, no study has
definitively established that persistent CD8+ T-cell activation during ART-mediated viral
suppression independently predicts subsequent CD4+ T-cell recovery. To address whether
persistent CD8+ T-cell activation independently predicts subsequent CD4+ T-cell recovery
during suppressive ART, we assessed the frequencies of activated CD8+ T cells and naïve
CD4+ T cells 3 to 5 years after starting suppressive ART and assessed the relationships
between these factors and subsequent CD4+ T-cell gains through up to 15 years of ART-
mediated viral suppression.
METHODS
This investigation examined HIV-infected individuals from the ACTG 372A study5 who
also enrolled in the ACTG long-term observational study ALLRT.6 The subjects began
protease inhibitor–based ART (indinavir + 2 nucleoside reverse transcriptase inhibitors
[NRTIs], zidovudine/lamivudine or stavudine/lamivudine) in 1996–1997 with CD4+ T-cell
counts ≤200 cells/mm3 or started dual NRTI treatment with CD4+ T-cell count ≤200 cells/
mm3 and subsequently added open-label indinavir to their dual NRTIs.5,7 At entry to the
372A study, subjects were randomized to add abacavir or placebo to their indinavir-based
regimen while virally suppressed (<500 copies/mL). Abacavir showed no additional effect.5
Of the 229 subjects in ACTG 372A (enrollment 1997–1998), 169 enrolled into ALLRT in
2000–2003; most (81%) enrolled in 2000. Follow-up in 372A included HIV RNA and CD4+
T-cell count measurements every 8 weeks. These were measured every 16 weeks in ALLRT.
For this investigation of long-term CD4+ T-cell count increases, the analysis was restricted
to the subset of 95 subjects with HIV RNA suppression (not having 2 consecutive RNA
measurements above 200 copies/mL since starting indinavir-based treatment8) and available
CD8 activation and naïve CD4 data.
CD8 activation (%CD38+/HLA-DR+ CD8+ T cells) and naïve CD4 percentage (%
CD45RA+/CD62L+ CD4+ T cells) were measured in ALLRT from 2000 to 2003 (every 16
weeks in 2000–2002; every 48 weeks in 2002–2003) using fresh cells and phenotyping at
multiple labs. Immune activation and the naïve CD4 percentage were fi rst measured
between 3 and 5 years after the start of indinavir-based regimen for most subjects (86%).
CD8 activation measurements during viral suppression were averaged for each subject; this
was done similarly for naïve CD4 percentage to reduce the impact of measurement error.
There was high within-subject correlation in CD8 activation (r = 0.78) and naïve CD4 (r =
0.90) percentages based on mixed-effects models, and levels of CD8 activation and naive
CD4 percentage did not change substantially over the 3 to 4 year timeframe from which the
averages were constructed (mean = 2.0 and 0.4 percentage points per year, respectively).
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Mean CD4+ T-cell counts were compared between groups (high vs low immune activation;
high vs low naïve CD4 percentage) using t tests. High immune activation was prespecifi ed
as CD8 activation above the median and similarly high naïve CD4 percentage was defi ned
as naïve CD4 percentage above the median. Mixed-effect models for longitudinal CD4+ T-
cell counts from years 3 to 15 after starting indinavir-based ART were used to
simultaneously assess the effect of CD8 activation and the naïve CD4 subset. To assess
whether persistently high CD8+ T-cell activation could independently predict reduced CD4+
T-cell count recovery, concurrent CD4+ T-cell counts were adjusted in another mixed-
effects model. This assessment is important because persistently high CD8+ T-cell
activation could conceivably be a consequence rather than a cause of a persistently low
CD4+ T-cell count recovery.
Long-term increases in CD4+ T-cell counts from the start of indinavir-based treatment (year
0) were analyzed. Available CD4+ T-cell measurements in a 12-month window around each
year were averaged for each subject for the data summarized by year. To provide a simple
descriptive summary, we averaged CD4+ T-cell counts from year 10 to 15 because CD4+ T-
cell counts tended to level off after year 10 and the available sample size after year 10
dropped substantially.
RESULTS
The 95 long-term suppressed subjects in this analysis were 92% male, 71% White non-
Hispanic, 11% Black non-Hispanic, and 15% Hispanic; 85 (89%) started indinavir in
combination with zidovudine and lamivudine and 10 (11%) in combination with stavudine
and lamivudine. At the time indinavir-based ART was initiated, the median CD4+ T-cell
count was 95 cells/mm3 (25th–75th percentiles: 37–149), the median HIV RNA copies/mL
level was 4.8 (25th–75th: 4.4–5.3) log10 (6 subjects had missing HIV RNA), and the median
age was 41 (25th–75th: 35–47) years.
Median follow-up was 15 (25th–75th: 9–16) years. Overall, the mean CD4+ T-cell count
increase from year 0 to year 5 was 296 (SD = 150) cells/mm3 and the increase from year 0
to the average of year 10 to 15 was 408 (SD = 189) cells/mm3.
The correlation between each subject’s mean CD8 activation percent and mean naïve CD4
percent was −0.24 (P = .017). The median CD8 activation percentage between
approximately years 3 to 5 of ART-mediated viral suppression was 18.5 (25th–75th: 12–27)
and the median naïve CD4 percent was 32 (25th–75th: 21–41).
Figure 1a displays long-term CD4+ T-cell counts stratifi ed by each subject’s average CD8
activation level. The mean CD8 activation levels in the low versus high immune activation
groups were 12.8% and 30%, respectively. Subjects with low CD8 activation levels on
virally suppressive treatment had signifi cantly greater CD4+ T-cell count increases during
follow-up, but had similar CD4+ T-cell counts at the time indinavir-based treatment was
started. Specifi cally, the mean CD4+ T-cell count increase from year 0 to year 5 and the
increase to the average of year 10 to 15 in the low CD8 activation group were 342 and 458
cells/mm3, and the increases were 248 and 349 cells/mm3 for the high CD8 activation group
(P = .002 and P = .016, respectively, comparing groups). At years 10 to 15, the mean CD4+
T-cell counts in the groups were 579 and 484 cells/mm3, respectively (P = .026).
Figure 1b similarly summarizes long-term CD4+ T-cell counts stratifi ed by each subject’s
average naïve CD4 percentage. The mean naïve CD4 percentages in the 2 groups were 21%
and 42%, respectively. Higher naïve CD4 percentages on treatment were associated with
signifi cantly greater CD4+ T-cell count increases during follow-up but similar CD4+ T-cell
counts at the time indinavir-based treatment was started. Mean CD4+ T-cell count increases
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from year 0 to year 5 and years 10 to 15 were 332 and 472 cells/mm3 in the high naïve CD4
group compared to 263 and 361 cells/mm3 in the low naïve CD4 group (P = .026 and P = .
016, respectively, comparing groups). At years 10 to 15, the mean CD4+ T-cell counts in the
groups were 586 and 498 cells/mm3, respectively (P = .038).
CD8 activation and naïve CD4 both remained signifi cant predictors (P < .01) when
simultaneously evaluated in a repeated measures model. Table 1 summarizes the effect of
higher CD8 activation on the continuous scale. In addition to the effects on CD4+ T-cell
count at year 10 (Table 1), higher CD8 activation and lower naïve CD4 percentage were
each signifi cantly associated with smaller increases in CD4+ T-cell counts from year 3
onwards in the model containing both factors (P < .01 for testing differences in slopes [see
Table A1]). In models that included both CD8 activation and naïve CD4 percentage, neither
CD4+ T-cell count nor HIV RNA level at the time indinavir-based ART was started were
predictive of long-term CD4+ T-cell counts (P = .20 and P = .48, respectively). Age,
however, was a signifi cant predictor (P = .015); younger subjects had greater CD4+ T-cell
count increases even after adjustment for level of CD8 activation and the naïve CD4 subset
on treatment. CD8 activation and naïve CD4 percentage remained as signifi cant predictors
(P < .01) when age was included in the model.
We further evaluated whether there was a differential effect of CD8 activation for different
levels of naïve CD4 percentage. There was a non-statistically signifi cant interaction in
terms of long-term CD4+ T-cell count increases (P = .10). Higher CD8 activation remained
associated with smaller long-term CD4+ T-cell count increases across the range of naïve
CD4 percentage (Table 1). Similarly, higher naïve CD4 percentage remained positively
associated with long-term CD4+ T-cell increases across the range of CD8 activation.
In sensitivity analyses, we examined the CD8 activation and naïve CD4 percentage in long-
term CD4+ T-cell counts using repeated measures (generalized estimating equation [GEE])
models that require fewer assumptions than the linear mixed model. Results (data not
shown) were similar to those in Table 1. Consistent fi ndings were also seen in GEE models
using square-root-transformed CD4+ T-cell counts. An analysis based on CD8 activation
and naïve CD4 percentage averaged over a narrower time-window also gave similar results
(data not shown). In addition, a sensitivity analysis was performed restricting to subjects
(and follow-up) with HIV RNA less than 50 copies/mL (n=52); fi ndings were generally
similar (see Figure 1c and 1d), and both higher CD8 activation and lower naïve CD4
percentage were signifi cant predictors when simultaneously evaluated in a repeated
measures model (data not shown). Last, we also found similar results (not shown) when
analyzing all 169 subjects with CD8 activation data and censoring the longitudinal CD4+ T-
cell counts at the time of confi rmed HIV RNA above 200 copies/mL.
Although both CD8 activation and naïve CD4 percentage were signifi cant predictors for
CD4+ T-cell recovery, they were not predictive after adjustment for concurrent CD4+ T-cell
count (P = .58 and P = .84, respectively) in mixed-effects models. Therefore, we cannot
exclude the possibility that immune activation is a consequence rather than a cause of CD4
recovery.
DISCUSSION
While persistent T-cell activation during suppressive ART has been cross-sectionally
associated with poor CD4+ T-cell recovery,1,2,9–11 it has remained unclear whether
persistent T-cell activation has a predictive effect on poor CD4+ T-cell recovery in long-
term studies. In the current study, we established that persistently high CD8+ T-cell
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activation and persistently low naïve CD4+ T-cell frequencies during ART-mediated viral
suppression predict fewer subsequent CD4+ T-cell gains.
A key clinical question of interest is whether interventions to reduce immune activation
might plausibly improve CD4+ T-cell recovery among HIV-infected individuals who have
already maintained viral suppression on ART but continue to have poor CD4+ T-cell
recovery. Indeed, many HIV-infected individuals experience incomplete CD4+ T-cell
recovery even after a decade or more of suppressive ART, and these individuals remain at
higher risk for mortality and other complications.12,13 While prior studies have established
that persistently high CD8+ or CD4+ T-cell activation during ART-mediated viral
suppression is cross-sectionally associated with poor CD4+ T-cell recovery,1–4 these prior
studies were unable to establish whether persistent immune activation was predictive of poor
CD4+ T-cell recovery since both measurements were assessed concurrently. Other studies
have established that pre-ART CD8+ T-cell activation predicts subsequent CD4+ T-cell
recovery during ART-mediated viral suppression.3,4 However, these latter studies only
supported the hypothesis that interventions to reduce immune activation at the start of ART
– such as earlier ART initiation – might plausibly improve ART-mediated CD4+ T-cell
recovery. Our current study is the fi rst to establish that persistent immune activation during
ART-mediated viral suppression predicts poor subsequent CD4+ T-cell recovery.
Our results are consistent with previous studies that examined CD4 counts over 12,3 and 3
years,1 respectively. This relationship has been affi rmed through this analysis of 15 years of
suppressive ART and is consistent with the recent observation that higher CD8 activation
during early ART-mediated viral suppression predicts increased subsequent mortality in a
Ugandan population.4
The causes of T-cell activation during ART-mediated viral suppression remain unclear, but
likely include ongoing release of HIV from latently infected cells and/or low-level
productive viral replication in tissue,14 persistent microbial translocation,15 and chronic viral
co-infections, particularly cytomegalovirus.16 The mechanisms mediating the relationship
between higher persistent immune activation and subsequent CD4+ T-cell recovery also
remain unclear, but may involve suppression of hematopoietic progenitor cell
proliferation,17 decreasing naïve and central memory T-cell survival through ongoing or
progressive lymphoid fi brosis,18 increased CD4+ T-cell apoptosis,19 or inhibition of CD4+
T-cell proliferation.20 These potential underlying causes and mechanistic consequences of
persistent immune activation may highlight targets for novel interventions to pursue in
clinical trials.
While lower pre-ART naïve CD4+ T-cell frequencies have previously been shown to predict
poor ART-mediated CD4+ T-cell recovery,2,20 the present work demonstrated for the fi rst
time that subjects with lower naïve CD4+ T-cell frequencies during suppressive ART
continue to have diminished subsequent CD4+ T-cell count increases. It remains unclear
whether persistently low naïve T-cell frequencies refl ect a lack of naïve T-cell and/or
hematopoietic progenitor cell production17 or decreased naïve CD4+ T-cell survival.18
Either way, both production and survival of naïve T cells can be increased with exogenous
IL-7 administration,21 so there may be interventions to improve naïve T-cell recovery in the
near future, though clinical benefi t still needs to be established.
Even though CD8 activation and naïve CD4+ T-cell frequencies were predictive of CD4+ T-
cell recovery, they were not signifi cant predictors after adjustment for concurrent CD4+ T-
cell counts. Causal effects of immune activation on CD4+ T-cell recovery cannot be
concluded. Further investigation of the complex interplay in the infl ammatory pathways
may provide signifi cant insight into the mechanisms.
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This was an observational study of virally suppressed subjects, and we did not examine
comparable nonsuppressed individuals. In addition, indinavir-based regimens are no longer
in common use; indeed most of our cohort had switched to non–indinavir-based regimens
during follow-up. This analysis could also have bias due to informative censoring, because
not all subjects were followed 15 years.
In summary, we have shown that higher levels of immune activation during virally
suppressive ART are associated with reduced CD4+ T-cell count reconstitution. These fi
ndings support research efforts to identify new approaches to reduce immune activation in
treated HIV disease.
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APPENDIX
Table A1
Effect of CD8 activation (% CD38+/HLA-DR+) and naïve CD4 percentage (% CD45RA+/
CD62L+) on the slope of change in CD4 outcome in virally suppressed subjects
Predictor
Effect on mean CD4 count per year (95% CI)
Separate univariate models
Model with both CD8 activation and
naïve CD4 percentage
CD8 activationa (per 5 percentage
points higher)
−3 (−5, −1) −3 (−5, −1)
Naïve CD4 %a (per 5 percentage points
higher)
3 (1, 4) 2 (1, −4)
a
Each subject’s average level, measured primarily during years 3–5, was used as the predictor.
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Mean CD4+ T-cell counts over time in virally suppressed subjects, using 200 copies/mL
virologic failure threshold for panels (a) and (b) and using a 50 copies/mL threshold for
panels (c) and (d), stratifi ed by (a) high versus low (>18.5% vs ≤18.5%) CD8+ T-cell
activation (% CD38+/HLA-DR), (b) high versus low (<32% vs ≤32%) naïve CD4+ T-cell
perentage (% CD45RA+/CD62L+), (c) high versus low (>18.9% vs ≤18.9%) CD8+ T-cell
activation (% CD38+/HLA-DR), (d) high versus low (>33% vs ≤33%) naïve CD4+ T-cell
percentage (% CD45RA+/CD62L+). CD8+ T-cell activation and naïve CD4+ T-cell
percentage were averaged levels measured primarily during years 3–5.
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Table 1
Effect of CD8 activation (% CD38+/HLA-DR+) and naïve CD4 percentage (% CD45RA+/CD62L+) on long-
term CD4 outcomes in virally suppressed subjects
Predictor
Effect on mean CD4 count at year 10 (95% CI)
Separate univariate models
Model with both CD8
activation and naïve
CD4 percentage Model with both factors and interaction
CD8 activationa (per 5 percentage
points higher)
−34 (−51, −18) −28 (−44, −12) Naïve CD4%=21% −30 (−48, −13)
Naïve CD4%=32% −28 (−44, −12)
Naïve CD4%=41% −26 (−44, −8)
Naïve CD4%a (per 5 percentage
points higher)
28 (16, 41) 24 (12, 36) CD8 activation=12% 22 (7, 37)
CD8 activation=18.5% 23 (10, 36)
CD8 activation=27% 25 (12, 38)
a
Each subject’s average level, measured primarily during years 3–5, was used as the predictor.
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